INtRODUCtION
During adolescence, the assessment of psychiatric symptoms and disorders is challenging. During this neurodevelopmental period, youth go through a period of body and psychic transformation and experience profound psychosocial and neurobiological changes (1) . Several authors have underlined the difficulty in discriminating between normal behaviors and psychiatric symptoms (2) . Normative adolescent experiences (e.g. imaginary audience and personal fable) can make the clinical picture blurred and lead to false positive psychiatric diagnoses, especially if non-validated diagnostic tools are administered and/ or the assessment is done by professionals that are not adequately trained (3) . In recent years, efforts have been devoted to develop diagnostic instruments and interviews that could help clinicians in differentiating between normal adolescent behaviors and psychiatric symptoms in this age range (4) (5) (6) . This is especially important as current research shows that 50% of mental disorders begin prior to 14 years of age and 75% have their onset by the age of 24 (7) . Furthermore, retrospective studies highlighted that the vast majority of youth receiving a psychiatric diagnosis had already been diagnosed of at least one mental disorder by the age of 11 (8) .
These findings support the need of specifically addressing to this neurodevelopmental period.
In children and adolescents, psychotic disorders are among the ten main causes of disability adjusted life years (9) . One of the most promising strategies to improve outcomes for these disorders is to detect symptoms of the emerging disorder in patients at Clinical High Risk for Psychosis (CHR-P hereafter) (10, 11) .
Over the last 3 decades, specific psychometric instruments have been developed and validated internationally to detect CHR-P individuals [for a meta-analysis of their prognostic accuracy see (12) ]. In adult samples it has been shown that these criteria associated with a 20% 2-year risk of developing psychosis [see eTable 4 in (13)] with the majority of patients who transition going to develop schizophrenia spectrum disorders (14) . The level of risk is highest in those meeting the Brief and Limited Intermittent Psychotic symptoms subgroup of the CHR-P criteria (15) and peaks within the first two years (16) . CHR-P individuals have an increased probability of developing psychosis that can be related to several environmental risk factors (17, 18) . Although there are different psychometric interviews available to identify CHR-P individuals (19) , overall they show a comparable prognostic accuracy which is also similar to that of other instruments used in preventive medicine (12) .
Beyond the risk of developing psychosis, several other studies have investigated the level of functioning and/or quality of life in CHR-P subjects (20) (21) (22) with controversial results. A recent meta-analysis found that CHR-P people have large impairment in functioning and worse quality of life than the healthy control group, similar to those observed in other coded psychiatric disorder (such as bipolar disorder). Moreover, only a small to moderate better functioning and similar quality of life compared with the psychosis group was highlighted (23) .
In a recent study (24) , the authors identified a factor structure composed of social-cognitive bias, reflective self (selfesteem, resilience, physical anhedonia and social anhedonia), neurocognition and pre-reflective self (magical ideation, perceptual aberration and basic symptoms) factors. These factors were not only different between recent-onset patients with schizophrenia, ultra-high risk for psychosis and healthy controls, but were also associated with baseline quality of life both in CHR-P individuals and psychotic patients.
Overall, the CHR-P field has attracted lot of interest to the point that clinically based operational criteria of attenuated psychosis syndrome (APS) have been introduced in the section III as well as in the main text (page 122) of the Diagnostic and Statistical Manual of Mental Disorder-Fifth Edition (DSM-5) (25) (26) (27) . The prognostic accuracy of the APS category appears similar to that of CHR-P psychometric instruments, at least in individuals seeking help at specialized early detection clinics (28) . Yet, the applicability and prognostic accuracy of the APS in adolescents is mostly undetermined (29, 30) . Several studies (31) (32) (33) agreed that transition risk to psychosis in adolescents is lower than that in adults, suggesting that the APS could be understanding of the clinical significance of CHR-P in adolescents, and shed new light on prognostic factors that can be used to refine the prediction of clinical outcomes and the implementation of preventive interventions. less specific in youth (34) . A recent study has confirmed that age has an effect on conversion rate to psychosis with lower rates in children and adolescents (35) . On another hand, children and adolescents APS appear to display a higher range of psychiatric symptoms and disorders and to have a higher risk of future psychiatric hospitalizations as well as lower functioning (36, 37) .
Candidate prognostic factors to refine the prediction of clinical outcome may include cognitive and neuropsychological factors (38, 39) . Available meta-analyses (40, 41) showed that CHR-P people performed significantly worse in verbal learning, visual learning and speed of processing, which also differentiated between CHR-P subjects that converted to psychosis and the ones that did not transition. However, the prognostic relevance of the factors in underage populations is not known.
For example, in a study conducted in a small sample of CHR-P adolescents the only parameter who differentiate those who converted to psychosis from the ones that do not at 6-years follow up was baseline low IQ (42) .
Recently, Lam et al. (43) found that cognitive dimensions are not only important in identifying youth that later convert to psychosis but account also for longitudinal changes in social and occupational functioning.
Other potential prognostic factors may be based on neuroimaging markers (14, 44, 45) .
White matter abnormalities have been identified in schizophrenia. It has been hypothesized that the presence of an aberrant cortical network and functional connectivity could play a key etiopathogenetic role in the disorder (46) .
To date, only a few studies have been conducted in CHR-P subjects where the integrity of white matter has been analyzed by using diffusion tensor imaging (DTI) technique (47) .
In a sample of 68 adolescents (33 CHR-P and 35 healthy controls) a significant reduction of fractional anisotropy of superior cerebellar peduncles was found (48) .
Other studies used resting state MRI scans and found alteration in the default mode (49) and salience networks connectivity (50) in CHR-P youth as compared to healthy controls.
The study protocol described here aims at filling these gaps in knowledge, with a longitudinal, broad risk approach, driven by the increasing need to refine the ability to predict different clinical outcomes in this population (51) .
AIMS
The primary aim of this study is to evaluate the 2-year prognosis in adolescent patients through three diagnostics groups: 1) with established DSM5 psychosis, 2) with CHR-P, and 3) with other psychiatric disorders other than psychosis or CHR-P. Stability of diagnosis will be evaluated in the patients who already have psychosis at baseline.
Transition to psychosis will be evaluated according to the CAARMS criteria. In more detail, the psychosis threshold will be considered crossed if the score in the Unusual Thought Content, Non-Bizarre Ideas, and Disorganized Speech will be as high as 6 in the global rating scale and the score in the Perceptual Abnormalities will be at least equal to 5 in the global rating scale. Patients will enter the psychosis group only if these symptoms are present for more than 1 week and their frequency is equal or higher than: 3-6 times a week for more than one hour per occasion or daily.
Socio-occupational functioning will be evaluated by means of the Social and Occupational Functioning Assessment Scale (SOFAS) (52) .
Development of other psychiatric conditions will be confirmed according to DSM-5 criteria.
The secondary aim is to study the effect of different prognostic factors (clinical factors, including family history, obstetric complications and drug use, neuropsychological and neuroimaging variables) influencing the clinical outcome.
MEtHODS AND ANALYSIS

Study Design and Population
We propose a longitudinal cohort study. The study will last 5 years in total with a recruitment period of 3 years, and each subject included will be assessed three times in a 2-year time span (baseline, 1-year and 2-year follow-up).
The study will be carried out in a third level center (Mondino Foundation, IRCCS, Pavia, Italy). The Mondino Foundation is a very well known National Specialist third level center that receives referrals in the field of child and adolescent neuropsychiatry from all over Italy (and in particular from the Lombardy region and the district of Pavia).
The sample will consist of adolescent patients aged 12-17 years, consecutively admitted to the inpatient or outpatient psychiatric units. Patients who already had a diagnosis of psychotic disorder (prior to assessment), established cognitive impairment (IQ < 70), neurological disorders, head injuries, or any other medical condition that could justify their psychiatric symptoms will be excluded.
Written informed assent and consent will be asked to both participants and their legal guardians, respectively.
Procedure
Each adolescent patient admitted to the psychiatric inpatient and outpatient units not presenting any of the exclusion criteria will be asked to take part in the study. The study procedure will be thoroughly explained by a trained psychologist to both patients and their legal guardian, and a written consent will be obtained. Patients will be free to ask additional questions and take their time in order to decide whether to take part or not in the study. Once patients and their caregivers consent to the study, the baseline assessment will take place.
Baseline and Follow-Up Assessments
Baseline At baseline sociodemographic information and previous medical and psychiatric history (previous psychiatric symptoms or diagnoses, medical/pharmacological or psychotherapy treatment) as well as socio-economic status [Four-Factor Index of Social Status, (53)] will be collected.
Patients will undergo an extensive diagnostic assessment that will include clinical interviews, semi-structured clinical interviews [CAARMS (54, 55) ; (Structured Clinical Interview for DSM-IV axis I and II, i.e. SCID-I and II (56) (57) (58) , Kiddie-schedule for Affective Disorder and Schizophrenia, i.e. K-SADS-PL (59, 60)), and self-administered questionnaires administered to both parents and patients (Child Behavior Checklist, i.e. CBCL) (61, 62) and Youth Self Report, i.e. YSR (63) ].
Based on this extensive clinical assessment, subjects will be divided into three subgroups: 1) adolescents with psychosis according to CAARMS criteria, 2) youth with other psychiatric symptoms that do not meet CHR-P or psychosis criteria, and 3) youth with other psychiatric symptoms that do not meet CHR-P criteria. The presence of psychiatric comorbidities will be recorded according to the DSM-5.
Self-administered questionnaires focusing on quality of life, distress, and family functioning will be completed by both guardians and parents. The clinician will complete specific scales describing the socio-occupational functioning and severity of the patient.
A thorough neuropsychological examination will be performed focusing on several cognitive domains: IQ, attention, reasoning and problem solving, verbal working memory, nonverbal working memory, verbal learning, and processing speed.
All the tests and questionnaires used are translated and validated into Italian.
A neuroimaging exam will complete the baseline examination. Patients will undergo a 3.0 Tesla magnetic resonance imaging (MRI) scan including a diffusion weighted sequence for DTI analysis (see MRI acquisition and processing section).
Follow-Up Assessments
Participants will be reassessed at 1-year and 2-year follow-up. Psychopathological, neuropsychological and functioning measures will be collected in the three subgroups. The same assessment as described in the baseline section will be carried out.
Neuroimaging exam will be performed at 2-year follow-up only. As this is a naturalistic longitudinal study, the research team will not interfere on the patient's care and treatment, which will consist of treatments as usual (psychosocial, pharmacological and psychotherapy).
Clinical Variables and Instruments
In the present study, the validated Italian version of the (CAARMS) (55) will be used to determine whether enrolled subjects met research criteria for CHR-P.
The CAARMS is a semi-structured interview designed to assess prodromal psychopathology for people at high clinical risk for psychosis. The CAARMS has a total of 27 items, which are clustered in seven subscales, of which the first one is used to identify the CHR-P criteria, as detailed elsewhere (34) .
This instrument has been shown to possess good to excellent concurrent, discriminant and predictive validity and excellent inter-rater reliability (54) . CAARMS interview will be administered only to patients.
In order to further validate the information obtained by the patient and to assess the presence of comorbidity and other DSM-5 Axis I, Kiddie-Schedule for Affective Disorder and Schizophrenia, i.e. K-SADS-PL (59, 60), interviews will be conducted with both patient and parents separately. Structured Clinical Interview for DSM-IV axis II, i.e. SCID II (57, 58) , will be administered to participants in order to verify the presence of personality disorders.
In addition, in order to gain the patient's and caregivers' perspectives on emerging problem behaviors, quality of life, perceived distress and family functioning, participants and legal guardians will be asked to fill in the following self-administered questionnaires: Child Behavior Checklist, i.e. CBCL (61) and Youth Self Report, i.e. YSR (63) ; EuroQoL scale (64, 65); Perceived Stress Scale (66, 67) ; and Family Adaptability and Cohesion Evaluation Scales (FACES-IV) (68, 69) .
All clinical measures will be administered by trained psychologist or neuropsychiatrist and collected both at baseline, 1-and 2-year follow-up.
Functioning Variables and Instruments
As one of the aims of this study is to evaluate the long-term prognosis and outcome also in terms of functioning, the level of functioning will be evaluated using the Children's Global Assessment Scale, i.e. CGAS (70) and the Social and Occupational Functioning Assessment Scale, i.e. SOFAS (52) as well as specific scales for role functioning [Global Functioning: Role scale, i.e. GF:R (71) and social functioning (Global Functioning: Social scale, i.e. GF:S (72, 73) ]. We will also use the Clinical Global Impression-Severity (CGI-S) scale (74) to assess overall severity of illness as assessed by clinicians.
These measures will be collected both at baseline, 1-year and 2-year follow-up.
Neuropsychological Domains and Instruments/Tests
In this study we aim at evaluating the longitudinal profiles of cognition in adolescents with CHR-P, compared with adolescents with psychosis and youth with other psychiatric symptoms that do not meet CHR-P criteria and to examine the possible role of specific cognitive deficits as predictors of outcome in this population. For this purpose, a trained psychologist will administer at baseline, 1-year follow-up, and 2-year follow-up the following extensive neuropsychological assessment focusing on several cognitive domains.
In particular the following cognitive domains will be explored: The whole assessment usually takes approximately 2h.
MRI Acquisition and Image Processing
Subjects will be examined on a Siemens Skyra 3 T MR scanner, equipped with a sixteen-channel head coil. The MRI protocol will include a high-resolution 3D T1-weighted sequence (MPRAGE: 160 sagittal slices, with 1mm thickness; TR/TE = 2300/2.98 ms; TI = 900 ms; flip angle = 9°, voxel size 1 mm 3 isotropic). A high angular resolution diffusion-weighted imaging (HARDI) dataset will be acquired as well, using a single-shot spin-echo echoplanar imaging (SE-EPI) sequence [66 contiguous axial slices acquired in an interleaved order, in-plane resolution = 2.2 mm 2 , slice thickness = 2.2mm, TR/TE = 8300/92 ms, flip angle = 90°, 64 non-collinear diffusion sensitization directions at b = 2000 s/ mm 2 , 1 at b = 0, and an integrated parallel acquisition technique acceleration factor (IPAT) of 2]. Image preprocessing will be performed through the FMRIB Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl/). For each subject, skull stripping will be applied to both the T1-weighted and the diffusion-weighted images (DWIs) using FSL's brain extraction tool. For the DWI dataset, eddy current distortions and motion artifacts will be corrected by registering each diffusionsensitized volume to the b0 volume with an affine transformation. After tensor diagonalization, whole-brain maps of the four main voxelwise quantitative WM metrics will be obtained [mean diffusivity (MD), fractional anisotropy (FA), axial diffusivity (AD) and radial diffusivity (RD)]. The T1-weighted images will be first registered (rigid body alignment) to the b0 volume of the DWI dataset and then to the Montreal Neurological Institute (MNI) standard stereotactic atlas using FSL's linear and nonlinear registration tool. DTI-derived voxelwise maps will be finally warped to the MNI space by applying the transform estimated for the coregistered T1 image.
Voxel-wise TBSS analysis will be performed using the default parameters in the FSL (82) . A mean FA image will be created and thinned to create a mean FA skeleton that represents the centers of all tracts common to both the entire group and the chosen subgroups (see subjects' section). Each subject's aligned DTI-derived maps will be then projected onto this skeleton, allowing voxel-wise between-group comparisons. Comparisons will be tested using a two-sample t-test adjusting for the subject's age and sex; correction for multiple comparisons will be applied [family-wise error (FWE), thresholded at p = 0.05.] Tractography will also be performed to identify the main white matter bundles, including the corticospinal tracts, forceps major and minor, the superior longitudinal fasciculus (SLF), the arcuate fasciculus (AF), the inferior frontal-occipital fasciculus (IFOF), the uncinate fasciculus (UF), the inferior longitudinal fasciculus (ILF). Average FA, AD, and RD will be evaluated along the entire reconstructed tracts.
Data Analysis Plan
Sample Size
Given the results of a preliminary feasibility study done by our group (83) , we expect to recruit 60 patients per year. We assume that approximately 20% of them will belong to the psychosis group, while the other 80% will be equally distributed in the other two groups.
As the recruitment period will last 3 years, the total sample will consist of 180 subjects of which 40 suffering from psychosis at baseline. On the basis of our preliminary data we expect a Hazard Ratio of developing psychosis in the CHR-P versus youth with other psychiatric symptoms not meeting CHR-P criteria not lower than 2.
Power
Using this Hazard Ratio, a power calculation indicates that a sample size of 180 subjects will be needed to detect a statistically significant difference with over 95% power.
Planned Statistical Analysis
Kaplan-Meyer survival analysis will be performed to calculate time-dependent cumulative probability to develop psychosis in the two non-psychotic groups.
Log-rank test will be performed to evaluate statistic significance of the raw risk.
Multivariate Cox regression model would be used to investigate the independent contribution to the probability to develop psychosis of the two diagnostic categories, controlling for all potentially confounding variables. The same model will be adopted to differentiate between confounding variables and variables independently contributing to the prognosis.
To calculate the probability to develop psychosis at 1 year and at 2 year in the different diagnostic groups, Markov chain will be performed.
DTI quantitative WM metrics (MD, FA, AD, and RD) for each patient at baseline and 2-year follow-up will be analyzed through Matlab software. Independent sample t-tests will be used to determine if there is a significant longitudinal difference in the three groups.
Ethics and Dissemination
The study protocol was reviewed and approved by the ethics committee of the Institute and all subjects will provide written informed consent in accordance with the Declaration of Helsinki.
DISCUSSION
As described above, research on high-risk state, especially APS, is still in its infancy in childhood and adolescents.
The results of our projects will be important in addressing the urgent need for studies in this area as well as criticism against the inclusion of APS diagnosis in DSM-5.
An innovative and important aspect of our study is its longitudinal design. To our knowledge, no previous study has ever evaluated the long-term outcome and clinical course of CHR-P in children and adolescents. Moreover, we have adopted the experimental approach to addresses the concept of a broader risk (84): prognosis encompass not only transition to psychosis, but the development of other DSM-5 diagnoses as well as evaluation of functioning in adolescents at risk.
Characterizing CHR-P subjects and identifying predictors of different clinical and functioning pathways, course and long-term outcomes represent a crucial step to enable risk stratification and personalized, risk-adapted treatment.
In particular, our data will enable a better understanding of the clinical significance of CHR-P and APS diagnosis in this age group. We will also evaluate the stability over time of CHR-P diagnosis and characterize its clinical course and socio-demographic, clinical, neuroimaging, and functioning correlates.
Overall, our data will raise knowledge in this research field by better characterizing clinically and functionally adolescents fulfilling CHR-P criteria. Moreover, it will provide information about CHR-P adolescent patients' specific needs and, thus, it will allow clinicians and researchers to plan more appropriate treatment options and evidence-based interventions.
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